4.0
Jun 11, 2020
Current employee, more than 3 years
Cambridge, MA
Recommend
CEO approval
Business Outlook
Pros
The science and the people are great and Biogen may be the first to launch an Alzheimer's drug and the company is going to change. The company seems to be ready for the transition but needs to set a clearer strategy and focus on execution. The company often feels good ideas are more important than their effective execution, so it will be interesting to see how Biogen adapts. Overall, good leadership and good science and great people. Still a meritocracy. A good response to COVID, too.
Cons
Typical bureaucracy, but they're aware of the problem. Some politics too, but what's everywhere.